Click here to read the Cover Story, "Expansion of DRCR network opens new research opportunities."
The protocol that has affected the way I practice the most is Protocol T. Protocol T was a three-arm, head-to-head study comparing the efficacy of aflibercept, ranibizumab and bevacizumab for center-involving diabetic macular edema (CI-DME) and decreased best corrected visual acuity, with these anti-VEGF drugs delivered in an individualized as-needed fashion over a 2-year time frame. This was the first study that showed any clinically meaningful differences in efficacy between the available
Uncategorized